Mylan announced on 14 July 2014 that it had entered into a definitive agreement with Abbott to acquire Abbott’s non-US developed markets specialty and branded generics business. The deal is intended to further diversify Mylan’s business and strengthen its commercial platform outside the US. The drugs covered in the deal include more than 100 specialty and branded generic pharmaceutical products in five major therapeutic areas (cardio/metabolic, gastrointestinal, anti-infective/respiratory, CNS/pain and women’s and men’s health) and include several patent protected, novel and/or hard-to-manufacture products with continued growth potential.

Pharma giant Pfizer announced on 16 July 2014 that it plans to acquire US-based generics maker InnoPharma for approximately US$360 million to strengthen its generics, injectable and ophthalmic products. InnoPharma’s current portfolio includes 10 generics approved by the US Food and Drug Administration (FDA). The company also has a pipeline of 19 products filed with FDA and more than 30 injectable and ophthalmic products under development.

Sun Pharmaceutical Industries announced on 16 July 2014 the acquisition of US-based sterile injectables maker Pharmalucence by one of its subsidiaries. The company is a leading manufacturer of radiopharmaceuticals and has developed injectables for cancer treatment.

Related article
Sun Pharma to acquire Ranbaxy creating 5th largest generics firm

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.